Related Experiment Video
Updated: Mar 27, 2026

Characterization and Isolation of Mouse Primary Microglia by Density Gradient Centrifugation
Published on: February 16, 2018
Microglial Inhibition Promotes Proliferation and Differentiation of Neural Stem Cells via STAT3/SDF-1/CXCR4 Signaling
Ao Ding1,2,3, Guiqin Duan4, Mingwei Zhu2
1Neurobiology Research Center, School of Medicine, Shenzhen Campus of Sun Yat-Sen University, Shenzhen, China.
Abstract:
Neonatal hypoxic-ischemic encephalopathy (HIE) may induce substantial neuronal damage. In particular, an overactivation of microglia following HIE represents a pathogenically important process. Previous studies have shown that microglial inhibitors can exert neuroprotective effects in HIE; however, the specific mechanisms underlying these effects have not yet been elucidated. Ligation of the left common carotid artery and exposure to 5% O2 were utilized to produce an HIE model in rats. A number of experimental approaches were then used to determine the effect of a microglial inhibition, achieved via the administration of GW2580, a Csf1r inhibitor, and investigate the mechanisms involved. Our HIE models exhibited substantial brain infarction and were significantly impaired in motor functions (p < 0.01-0.001, in all tests examined). In the infarction areas, the number of microglia, macrophages, and neural stem cells (NSCs) was all dramatically increased over that in sham-injured rats, respectively (p < 0.05-0.001). The administration of GW2580 significantly reduced the numbers of microglia and macrophages, but increased the number of NSCs when compared to those in vehicle-treated HIE models (p < 0.05-0.001). Furthermore, GW2580 significantly ameliorated both the histological and behavioral phenotypes in HIE rats and increased STAT phosphorylation (p < 0.05-0.001). Finally, the inhibition or activation of STAT3 respectively decreased or increased the neuroprotective effects of GW2580 (p < 0.05-0.001). Collectively, our findings demonstrate that the STAT3 signaling pathway plays a critical role in the neuroprotective effects of microglial inhibition and may facilitate the development of novel therapeutic strategies to treat stroke.
Insights
Microglial inhibitors like GW2580 show neuroprotective effects in neonatal hypoxic-ischemic encephalopathy (HIE) by modulating neural stem cells and activating the STAT3 pathway. This research offers new therapeutic strategies for stroke treatment.
Area of Science:
- Neuroscience
- Cell Biology
- Pharmacology
Background:
- Neonatal hypoxic-ischemic encephalopathy (HIE) causes significant neuronal damage, with microglial overactivation being a key pathological process.
- Previous research suggests microglial inhibitors offer neuroprotection in HIE, but the underlying mechanisms remain unclear.
Purpose of the Study:
- To investigate the neuroprotective mechanisms of microglial inhibition using GW2580, a Csf1r inhibitor, in a rat model of HIE.
- To elucidate the role of the STAT3 signaling pathway in mediating the effects of microglial inhibition.
Main Methods:
- A rat model of HIE was established using carotid artery ligation and hypoxia.
- GW2580 was administered to inhibit microglia, and its effects on brain infarction, motor function, cell populations (microglia, macrophages, neural stem cells), and STAT3 phosphorylation were assessed.
- STAT3 inhibition or activation was used to further explore its role.
Main Results:
- HIE induced significant brain infarction and motor deficits.
- GW2580 treatment reduced microglia and macrophage numbers, increased neural stem cell counts, and ameliorated histological and behavioral impairments.
- GW2580 administration increased STAT3 phosphorylation, and STAT3 modulation affected the drug's neuroprotective efficacy.
Conclusions:
- Microglial inhibition via GW2580 demonstrates significant neuroprotective effects in HIE models.
- The STAT3 signaling pathway is critically involved in mediating the neuroprotective benefits of microglial inhibition in HIE.
- These findings suggest potential for developing novel therapeutic strategies for stroke targeting microglial function and STAT3 signaling.

